A comparative study of amyloid-beta (I-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator

Thrombosis and Haemostasis

Volumn 92, Issue 3, 2004, Pages 559-567

  Kruithof, Egbert K O ^a   Schleuning, Wolf Dieter ^b  

^a Faculty of Medicine   (Switzerland)

^b NOXXON PHARMA AG   (Germany)

Author keywords

Amyloid beta; Cofactor; Fibrin; Fibrinogen; Plasminogen activator

Indexed keywords

ALTEPLASE; AMYLOID BETA PROTEIN[1-42]; CHROMOGENIC SUBSTRATE; DESMOTEPLASE; FIBRIN; FIBRINOGEN; PLASMIN; PLASMINOGEN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; FIBRINOLYTIC THERAPY; HUMAN; INCUBATION TIME; MATHEMATICAL ANALYSIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SIDE EFFECT; STROKE;

AMYLOID BETA-PROTEIN; ANIMALS; CHIROPTERA; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; KINETICS; PEPTIDE FRAGMENTS; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 4544219792     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-02-0058     Document Type: Article

References (26)

1. Carroll PM, Tsirka SE, Richards WG, et al. The mouse tissue plasminogen activator gene 5′ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 1994; 120: 3173-83.
2. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270: 1992-4.
3. Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-9.
4. Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
5. Bergum PW, Gardell SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis. J Biol Chem 1992; 267: 17726-31.
6. Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25596-603.
7. Wardlaw JM, Sandercock PA, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis. Stroke 2003; 34: 1437-42.
8. Yepes M, Sandkvist M, Moore EG, et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-40.
9. Wang X, Lee SR, Arai K, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9: 1313-7.
10. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000; 31: 3034-40.
11. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-6.
12. Fukuda S, Fini CA, Mabuchi T, et al. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004; 35 (4): 998-1004.
13. Tsirka SE, Gualandris A, Amaral DG, et al. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
14. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.
15. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-25.
16. Liberatore GT, Samson A, Bladin C, et al. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-43.
17. Kingston IB, Castro MJ, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat Med 1995; 1: 138-42.
18. Wnendt S, Wetzels I, Gunzler WA. Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb Res 1997; 85: 217-24.
19. Praus M, Kettelgerdes G, Baier M, et al. Stimulation of plasminogen activation by recombinant cellular prion protein is conserved in the NH(2)-terminal fragment PrP23-110. Thromb Haemost 2003; 89: 812-9.
20. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81: 741-66.
21. Iadecola C. Cerebrovascular effects of amyloid-beta. peptides: mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol 2003; 23: 681-9.
22. Nunan J, Small DH. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 2000; 483: 6-10.
23. Davis J, Xu F, Deane R, et al. Early-onset and robust cerebral microvascular accumulation of amyloid {beta}-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid {beta}-protein precursor. J Biol Chem 2004; 279: 20296-306.
24. Maat-Schieman ML, Yamaguchi H, van Duinen SG, et al. Age-related plaque morphology and C-terminal heterogeneity of amyloid beta in Dutch-type hereditary cerebral hemorrhage with amyloidosis. Acta Neuropathol (Berl) 2000; 99: 409-19.
25. Jones AJ, Meunier AM. A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 1990; 64: 455-63.
26. Van Nostrand WE, Porter M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity. Biochemistry 1999; 38: 11570-6.